The use of adalimumab in the management of refractory Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 27, Issue 4, 2008, Pages 308-315

  Ho, G T ^a   Smith, L ^a   Aitken, S ^a   Lee, H M ^a   Ting, T ^a   Fennell, J ^a   Lees, C W ^a   Palmer, K R ^a   Penman, I D ^a   Shand, A G ^a   Arnott, I D ^a   Satsangi, J ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; PREDNISOLONE; SALAZOSULFAPYRIDINE; TACROLIMUS;

ADULT; ALLERGIC REACTION; ANAPHYLAXIS; ARTHROPATHY; ARTICLE; CELLULITIS; CLINICAL ARTICLE; COLON PERFORATION; CROHN DISEASE; DELAYED HYPERSENSITIVITY; DIABETES MELLITUS; DRUG COST; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HAIR LOSS; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; INFECTION; LIVER DYSFUNCTION; LUNG CANCER; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PSOAS ABSCESS; REMISSION; SEPSIS; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COHORT STUDIES; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38149077059     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03583.x     Document Type: Article

References (18)

1. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002 359:1541 9.
2. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999 340:1398 405.
3. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005 128:1805 11.
4. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005 353:2462 76.
5. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006 130:323 33.
6. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007 132:52 65.
7. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007 56:1232 9.
8. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007 146:829 38.
9. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007 357:228 38.
10. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007 357:239 50.
11. Sandborn WJ, Hanauer S, Loftus EV Jr., et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 2004 99:1984 9.
12. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007 44:265 7.
13. Peyrin-Biroulet L, Laclotte C, Roblin X, Bigard MA. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol 2007 13:2328 32.
14. Gaya DR, Aitken S, Fennell J, Satsangi J, Shand AG. Anti-TNF-{alpha} therapy for orofacial granulomatosis: proceed with caution. Gut 2006 55:1524 5.
15. Kaplan GG, Hur C, Korzenik J, Sands BE. Infliximab dose escalation versus initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis. Aliment Pharmacol Ther 2007 26:1509 20.
16. Hanauer SB. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Gut 2007 56:1181 3.
17. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006 295:2275 85.
18. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006 54:2368 76.